



Features, key achievements and perspectives of the Global-PPS on AMC and HAI - Towards a promising synergy between WHO-PPS and Global-PPS



Ann Versporten
Global-PPS coordination team
University of Antwerp, Belgium
29 June 2025



@Global-PPS
@GlobalPPS_comm

www.global-pps.com



The Global-PPS is coordinated by the University of Antwerp and supported by bioMérieux

Global-PPS – Birth



The 4th Edition of the
World HAI Forum on HAI
and Antimicrobial
Resistance – June 2013
Annecy, France

bioMérieux funding

University of Antwerp,
Belgium
→ European Surveillance
of Antimicrobial
Consumption (ESAC-PPS)

Antimicrobial Resistance
and Prescribing in
European Children
(ARPEC-PPS)



First
worldwide
Global-PPS
53 countries
335 hospitals
Expansion
network

2006 - 2007 - 2008 - 2009

2010 - 2011 - 2012

2013

2014

2015

2016-2017

European funding

- Amadeo B. et al, JAC 2010,
- Zarb P. et al, JAC 2011, *Drugs* 2011, *CMI* 2012, *Drugs Aging* 2012.

- Versporten A. et al, PIDJ 2013, JAC 2016;
- Jafar Soltani et al, Erciyes Med J. 2019.
- Hufnagel M. et al, JPID. 2018
-

G-PPS
Protocol
development
Development
Web-based tool
Global-PPS
pilot (33 hosp)

Any hospital admitting
inpatients is welcome to
participate

Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey

Ann Versporten, Peter Zarb, Isabelle Cariaux, Marie-Françoise Gros, Nico Drapier, Mark Miller, Vincent Jarlier, Dilip Nathwani, Herman Goossens, on behalf of the Global-PPS network*

Summary

Background The Global Point Prevalence Survey (Global-PPS) established an international network of hospitals to measure antimicrobial prescribing and resistance worldwide. We aimed to assess antimicrobial prescribing and resistance in hospital inpatients.

Methods We used a standardised surveillance method to collect detailed data about antimicrobial prescribing and resistance from hospitals worldwide, which were grouped by UN region. The internet-based survey included all inpatients (adults, children, and neonates) receiving an antimicrobial who were on the ward at 0800 h on one specific day between January and September, 2015. Hospitals were classified as primary, secondary, tertiary (including infectious diseases hospitals), and paediatric hospitals. Five main ward types were defined: medical wards, surgical wards, intensive care units, neonatal wards, and medical intensive care units.

Lancet Glob Health 2018; 6: e939-29
Published Online
April 19, 2018
http://dx.doi.org/10.1016/S2214-1099(18)30386-4
*Members listed at the end of the paper
Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute



@Global-PPS
@GlobalPPS_comm

www.global-pps.com



Global-PPS – How we've grown

Renewed website 7 languages

www.global-pps.com/

Reinforcement Global-PPS team

1st worldwide
Global-PPS 53
countries
335 hospitals

Expansion
network

Coordination
team

Development
HAI module
Launch Sept'19

Communication
capacity

IT
capacity

Protocol
development
Sept'22 Test
Outpatient
module

Extension
G-PPS tool
May '23
Worldwide launch
Outpatient module

2014 2015 2016-2017 2018 2019 2020 2021 2022 2023 2024 2025

G-PPS
Pilot

3 surveys/
year

Start collaboration
MSF
CwPAMS

COVID-19
pandemic
Drop
participation

Recovery
participation

Kick-off
drive-AMS

Launch ADILA

Launch Pfizer outpatient project

SPARC-PPS

Launch
qualitative
research

Any
institution/hospital/PHC
admitting outpatients is
welcome to participate

Launch G-PPS survey
focus on AMS : barriers/facilitators

Pauwels et al. Antimicrob Resist Infect Control (2021) 10:138
<https://doi.org/10.1186/s13756-021-01010-w>

Antimicrobial Resistance
and Infection Control

RESEARCH

Open Access

Assessing the impact of the Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (Global-PPS) on hospital antimicrobial stewardship programmes: results of a worldwide survey

Ines Pauwels^{1*}, Ann Versporten¹, Helene Vermeulen², Erika Vlieghe^{3,4} and Herman Goossens¹



@Global-PPS
@GlobalPPS_comm

www.global-pps.com

Why a Global-PPS ?



- Global-PPS complies with WHO global action plan on antimicrobial resistance.
- Global-PPS meets its strategic objectives:
 - Improve **awareness** and understanding of antimicrobial consumption and resistance
 - Strengthen **knowledge** through surveillance and research
 - instrumental in planning and supporting **national & local stewardship interventions**
 - Enhance **appropriate use** of antimicrobials
 - Reduce the **incidence of infection**
 - Ensure sustainable investment in countering **antimicrobial resistance**.



Identify burden



Determine variation in **drug, dose & indications** of antimicrobial prescribing



Create a “longlist” **quality indicators for prudent AM prescribing** which includes metrics, targets & risk factors for HAI

Change practice




Help design feasible, tailored **stewardship interventions**

Assess effectiveness of **interventions** through repeated G-PPS





Measure impact

Global-PPS surveillance tool in a nutshell



All hospitals worldwide can participate – voluntary basis

Benefits : Real-time data collection and feedback



➤ Instruction manuals, Tutorial video's; Training webinars : <https://www.global-pps.com/events/>



- Own raw data supplemented with standardized variables (Excel)
- One-point and merged feedback with benchmark (pdf)
- Interactive feedback reporting dashboard with benchmark (G-PPS application)

Antimicrobial quality indicators obtained from Global-PPS



- Prevalence of antimicrobial use
- Classes of antimicrobials being used: **broad spectrum or narrow spectrum?**
- **Ratio Access-Watch** (AWaRE) antibiotics
- **Indications** for antimicrobials: community- or hospital-acquired infections, medical or surgical prophylaxis?
- Antibiotics agents are being used for **particular infections and for SP** ?
- Are there **local guidelines** missing for certain indications?
- Are the antimicrobials prescribed according local guidelines?
- Has a clear **reason for prescription** been recorded?
- Has a clear **duration of treatment** or **stop date** been recorded?
- Duration of antibiotics for surgical prophylaxis?
- Antimicrobial treatment **targeted**?

Where to get started?



From Global-PPS to Antimicrobial Stewardship (AMS)



Provides insight into your institution's antimicrobial prescribing patterns



Evaluate your antimicrobial stewardship activities

- Repeated PPS measurements to assess effectiveness of your interventions



Create awareness on appropriate antimicrobial prescribing

- Communicate PPS results to everyone involved (clinicians, pharmacists, nurses, management...)




The drive-AMS project




- Collaboration with Radboudumc and four European partner countries: Greece, Lithuania, Portugal, & Romania
- Data-driven, behavioural change approach to implementing AMS
- Global-PPS also involved in African countries (ICARS)

Degree of participation to the Global-PPS



- 2015: 53 countries
2025: 100 countries
- 2015: 335 unique hosp.
2025: >1600 unique hosp.
- 2015: 100.600 patients
2025: >690.000 patients

Degree of participation Global-PPS 2015-2025



- ☐ 23 African countries
(with validated data as of 20 June '25)
- ☐ 423 hospitals
- ☐ 673 validated surveys



Importance of networking and communication

Enhance continued **collaborations worldwide** with international, national and local organizations.

- ✓ Networks have grown (South Africa, Ghana)
- ✓ Renewed collaboration with MSF (e.g. South Soudan)
- ✓ Collaboration WHO-PPS with G-PPS

Global-PPS website : www.global-pps.com



- Central hub for information, regularly updated
- 6 different languages
- Instrumental in disseminating info to relevant stakeholders

- <https://www.global-pps.com/timeline/>
- FAQ list : <https://www.global-pps.com/faq/>
- Regular organized free Global-PPS webinars
- Protocols
- 2 Selections of Publications
- Leaflets
- Testimonials
- > 50 news articles
- >110 abstracts/posters
- > 50 scientific publications
- Videos and other communications



www.global-pps.com

[pps.com](http://www.global-pps.com)





Thanks to the continued financial support from bioMérieux



Disclosures: “bioMérieux is the sole private sponsor of the Global-PPS. The funder has no role in study design, data collection, data analysis, data interpretation, or writing the report. Data are strictly confidential and stored anonymous at the coordinating centre of the University of Antwerp, Belgium.”



Harmonisation trajectory of Global-PPS and WHO-PPS on Antimicrobial Consumption, HAI and Resistance



Global-PPS (2014) and WHO-PPS (2019) : parallel methodologies yet differences

- Confusion / hesitance in hospitals worldwide
- Duplication of efforts

Aims :

- **Harmonization** to enable hospitals to participate in Global-PPS or WHO-PPS with a **single dataset**.
- Inform **jointly hospital-based tailored antimicrobial stewardship (AMS) interventions** to curb AMR worldwide.



Harmonisation trajectory of Global-PPS and WHO-PPS – Methodology –



2024: Start collaboration on joint methodology and interoperable PPS approach :
scope, common goals, differences in methodologies, services and possible adjustments to reach harmonization

Ongoing steps:

- **Explore in-depth differences** between the two systems
- Obtain one **common protocol** and **data collection templates**
- Define governance



Harmonisation trajectory Global-PPS and WHO-PPS

– Results –

Main differences identified:

- 1) Regulatory scope
- 2) Survey initiation and frequency
- 3) Amount of detailed patient characteristics
- 4) Antimicrobials studied
- 5) Tools for data entry and validation
- 6) Feedback reporting and training
- 7) Data ownership
- 8) Outpatient module for the Global-PPS only





Global-Point Prevalence Survey (Global-PPS) and WHO-PPS on Antimicrobial Use, HAI and Resistance

Ann Versporten¹, Arno Muller², Martina Escher², Ines Pauwels¹, Deborah Tong², Annelies Boven¹, Verica Ivanovska², Benedikt Huttner², Erika Vlieghe^{1,2}
¹University of Antwerp, Global Health Institute, Belgium; ²WHO Geneva, Switzerland; ³University Hospital Antwerp, Belgium
Contact : global-PPS@uantwerpen.be / glass-amc@who.int



ESCMID Global 2025 (poster E0220)

BACKGROUND & OBJECTIVES

A Point Prevalence Survey (PPS) is used for the assessment of antimicrobial use (AMU) and healthcare Associated Infections (HAI) in healthcare settings worldwide.

- Global-PPS (2014) and WHO-PPS (2019) have developed parallel methodologies, yet differences exist which involve challenges in a time of constrained public health investments:
 - confusion / hesitance in hospitals worldwide
 - duplication of efforts
- Aim : Harmonization between Global-PPS and WHO-PPS that would enable hospitals to participate in Global-PPS or WHO-PPS with a single dataset.
 - inform jointly hospital-based tailored antimicrobial stewardship (AMS) interventions to curb AMR worldwide.

METHODS

- 2024: Start with a series of online meetings between scientific and operational teams from Global-PPS and WHO-PPS.
 - Evolve towards a joint methodology : describing actual scope, aims of both PPSs, methodologies and services offered in both systems.
 - Interoperable PPS approach : defining common goals, differences and possible adjustments to reach harmonization.
- Step 1: Explore in-depth differences between the two systems and obtain one common protocol and data collection templates.
- Iterative process: implementation of harmonization steps to progressively achieve an interoperable PPS system.
- Step 2: Update web-based application and obtain exchanged web-based data involving technical IT expertise.
- Next steps: Develop coordinated feedback reporting, governance, data sharing process, communication,...

RESULTS : comparing Global-PPS and WHO-PPS data collection systems for inpatients

Main differences identified: 1) survey initiation and frequency, 2) amount of detailed patient characteristics, 3) antimicrobials studied, 4) tools for data entry and validation, 5) availability of feedback reporting and training, 6) data ownership, 6) outpatient module available for the Global-PPS only.

	Global-PPS	WHO-PPS
Regulatory scope	Worldwide voluntary participation for single or network of hospitals.	Nomination via Ministry of Health at regional, national and single hospital level.
Main aim	Surveillance antimicrobial use (AMU) / Data-driven sustainable capacity building on antimicrobial stewardship (AMS).	Surveillance AMU / Public Health to inform national AMS policies and hospitals AMS programmes.
Frequency, national sampling	Maximum 3 surveys/year between Jan-April, May-August, September-December.	Surveys at least every 2 years at supranational, national (pool of hospitals selected representatively or conveniently), and single hospital levels.
Modularity	Target any hospital or healthcare facility where patients are admitted: basic + optional HAI module targeting invasive devices.	Target healthcare facilities for acute care: one main module with core and optional variables (process indicators and HAI)
Within hospital sampling	No patient-level sampling, but possibility to target selected ward types if repeated PPS.	Sampling of patients for hospitals >500 beds while including all wards (1 out of 2/3 patients depending on hospital size).
Eligible patients	Denominator: 'all' inpatients at 8am in included wards on day of PPS. Numerator: 'all' inpatients with ongoing antimicrobial (AM) prescription. Sampling at patient level not allowed to ensure comprehensive data coverage + avoid selection bias.	Denominator: sampled inpatients at 8am of included wards on day of PPS. Numerator: sampled inpatients with an ongoing antibiotic prescription.
Collection detailed patient characteristics	Only for inpatients on AM. For all inpatients: details on indication (medical, surgical, ICU); for HAI module: use invasive devices.	Systematically collected for all eligible inpatients: age/gender, admission date, underlying conditions and risk factors, use of invasive devices.
Antimicrobials (AM) targeted	Antibiotics (J01, A07AA, P01AB), antimycotics (J02), antifungals (D01BA), antivirals (J05), anti-TB drugs (J04A), antimalarials (P01B)	Antibiotics (J01, A07AA, P01AB)
Collection of detailed AM prescribing information	Detailed AM data collection starts from AM prescription, each linked to 1 diagnosis with unlimited number of AM for same or different diagnosis. For each AM: dose, frequency, route of administration is reported.	Detailed antibiotic data collection starts from indication with max of 4 indications, each assigned max 6 antibiotics. One antibiotic can be linked to multiple indications. For each antibiotic: dose, frequency, route of administration is reported.
Process quality indicators	Include culture sample taken and which one, use of biomarker or WBC to guide therapy, reason in notes, surgical prophylaxis duration, guideline compliance (type), stop/review date, missed doses, treatment type (targeted/empiric).	Include culture sample taken and which one, reason in notes, surgical prophylaxis duration, and optionally oral switch, parenteral type, missed doses, guideline compliance (type), treatment type (targeted/empiric), prescriber type.
Data entry and feedback reporting	Web-based application for data entry, validation, export of own raw data supplemented with ATC codes, AWaRE class, ... (Excel). Real-time feedback reporting with benchmarking results at country, region & hospital type (Pdf + interactive feedback dashboard for customized analyses).	Countries/hospitals build own data entry & analysis tool beside available WHO tool for data entry & analysis (Excel). Online application for data entry/data upload, data validation, automatic reports and raw data download under development in DHIS2.
National form & hospital characteristics	Geographical information reported during web-based data entry. Infrastructure, policy and practice for diagnostic and antibiotic stewardship captured via hospital profile (structure indicators).	Hospital profile: Characterise national level surveys, captures infrastructure, policy and practice for diagnostic and antibiotic stewardship + several variables on hospital size (structure indicators).
Training & support	Regular training webinars on method and interpretation results, translated protocols and materials, FAQ and antimicrobial list, tutorial videos on data entry, helpdesk.	Training through country visits + provided on demand: data entry & analysis.

CONCLUSION

- Identified differences can be harmonized through (1) adaptations in both data collection systems and (2) the implementation of an interoperable IT infrastructure.
- Ultimately, harmonization simplifies data collection, entry, validation, feedback reporting and interpretation.
- A single unified method would enable hospitals and countries to focus on data-informed, contextualized AMS interventions.

Disclosures: bioMérieux is the sole industrial partner of the Global-PPS. The company has no role in study design, data collection, data analysis, data interpretation, or writing the report. Data are strictly confidential and stored anonymously at the coordinating centre of the University of Antwerp.

Scan for more info on Global-PPS





@Global-PPS
@GlobalPPS_comm

www.global-pps.com

Presented at ESCMID Global 2025

Harmonisation trajectory of Global-PPS and WHO-PPS – Methodology –

Joint methodology and interoperable PPS approach

Future steps :

- Update web-based application and obtain exchanged web-based data involving technical IT expertise
- Develop coordinated feedback reporting, data sharing process, communication,...

Global-PPS planning 2025 and beyond

- **Three survey periods continue to be available:**
 - ✓ January - April / May - August / September – December
- Continuous improvements on **real-time feedback reporting:**
 - ✓ One-point and merged feedback reports (pdf)
 - ✓ Interactive, real-time, longitudinal feedback reporting dashboard



Inpatient Global-PPS protocol → Implementation new harmonized Global-WHO-PPS protocol in 2026



Outpatient Global-PPS protocol → See presentation Annelies Boven

Discussion : The way forward in support of AMS in African countries

Thank
~ you

